Bain Capital Life Sciences Investors, LLC Q4 2020 Filing
Filed February 16, 2021
Portfolio Value
$1.6T
Holdings
26
Report Date
Q4 2020
Filing Type
13F-HR
All Holdings (26 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | SWTXSPRINGWORKS THERAPEUTICS INC | 7,281,307 | $528.0B | 33.15% | |
| 2 | AVIRATEA PHARMACEUTICALS, INC. | 5,615,659 | $234.6B | 14.73% | |
| 3 | ARQTARCUTIS BIOTHERAPEUTICS, INC. | 3,979,292 | $111.9B | 7.03% | |
| 4 | —MERSANA THERAPEUTICS | 3,445,667 | $91.7B | 5.76% | |
| 5 | ANNXANNEXON INC | 3,241,628 | $81.1B | 5.09% | |
| 6 | —DICERNA PHARMACEUTICALS INC | 3,080,237 | $67.9B | 4.26% | |
| 7 | —SYROS PHARMACEUTICALS, INC. | 5,785,036 | $62.8B | 3.94% | |
| 8 | CCCCC4 THERAPEUTICS, INC. | 1,642,209 | $54.4B | 3.42% | |
| 9 | SLDBSOLID BIOSCIENCES INC | 7,060,353 | $53.5B | 3.36% | |
| 10 | DVAXDYNAVAX TECHNOLOGIES CORP | 10,895,773 | $48.5B | 3.04% | |
| 11 | NRIXNURIX THERAPEUTICS, INC. | 1,284,314 | $42.2B | 2.65% | |
| 12 | —CONSTELLATION PHARMACEUTICALS, INC. | 1,400,000 | $40.3B | 2.53% | |
| 13 | —APTINYX INC | 8,891,758 | $30.8B | 1.93% | |
| 14 | KYMRKYMERA THERAPEUTICS INC. | 479,605 | $29.7B | 1.87% | |
| 15 | AGLEUSDAEGLEA BIO THERAPEUTICS | 2,700,000 | $21.2B | 1.33% | |
| 16 | —MARINUS PHARMACEUTICALS INC | 1,431,058 | $17.5B | 1.10% | |
| 17 | CRNXCRINETICS PHAMACEUTICALS | 1,071,428 | $15.1B | 0.95% | |
| 18 | —THERAPEUTICS ACQUISITION COR | 1,000,000 | $13.9B | 0.87% | |
| 19 | —ARYA SCIENCES ACQUISITION CORP III | 1,000,000 | $10.8B | 0.68% | |
| 20 | ASNSUSDX4 PHARMACEUTICALS INC | 1,648,485 | $10.6B | 0.67% | |
| 21 | YB4PSAVARA INC | 5,128,593 | $5.9B | 0.37% | |
| 22 | —BCTG ACQUISITION CORP | 500,000 | $5.7B | 0.36% | |
| 23 | —BCLS ACQUISITION CORP | 487,500 | $5.4B | 0.34% | |
| 24 | —FRAZIER LIFESCIENCES ACQUISITION CORP | 300,000 | $3.1B | 0.20% | |
| 25 | —JIYA ACQUISITION CORP | 300,000 | $3.1B | 0.19% | |
| 26 | MLTXHELIX ACQUISITION CORP | 250,000 | $2.8B | 0.18% |